Dr Paolo Ghia presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the ASCEND study.

Patients with relapsed or refractory chronic lymphocytic leukaemia were randomised to receive either acalabrutinib or the investigator choice of rituximab plus idelalisib (IdR) with acalabrutinib showing a much improved PFS and safety profile.